EAS Newsletter July 23, 2024
Society: Don’t let this opportunity pass you by. Apply for an EAS Competitive grant Don’t let this opportunity pass you by! Submit your application for…
Society: Don’t let this opportunity pass you by. Apply for an EAS Competitive grant Don’t let this opportunity pass you by! Submit your application for…
Society: Don’t let this opportunity pass you by. Apply for an EAS Competitive grant Don’t let this opportunity pass you by! Submit your application for…
Atherosclerotic cardiovascular disease (ASCVD) remains to be the leading cause of mortality and disabilityworldwide. Atherosclerosis, the underlying cause of cardiovascular disease (CVD), begins early in…
Governance: Announcing the newly elected Executive Committee members We are delighted to announce the winners of the 2024 Executive Committee election. We extend our sincere…
We are pleased to announce the conclusion of the EAS 2024 elections and extend our congratulations to the following individuals: Post of Vice-President 2025-2028Jeanine Roeters…
Gene therapy in lipid metabolism and CVD by Prof Sekar Kathiresan Sekar Kathiresan is the Chief Executive Officer and founder of Verve Therapeutics, US. Previously,…
We would like to extend our gratitude to all members who participated in the voting process. The election has now concluded. The votes will now…
Governance: Last days to vote in the EAS Executive Committee Elections This is your final reminder to cast your vote in the EAS Executive Committee…
Log in to view the election update. With less than a week remaining, we are excited to share the current election statistics with you. These…
Governance: Don’t wait to cast your vote. This is your opportunity to step up and contribute to making EAS even better Don’t wait to cast…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.